It's Not About the Technology is about a phenomenon most dreaded by high-technology industry executives: a failure at the execution leading to a missed market window. High-tech executives agree that a critical factor that drives the company to such a failure is the breakdown of interaction between marketing and engineering. This book is predicated on the notion that the success of execution lies neither in the technology nor in the market strategy. On the contrary, it is shaped by the context of an individual, whether an engineer or a marketer. From this viewpoint, successful execution in a high-tech company is manifest in a confluence of 3 contexts: the technological, the customer and the economic contexts. This book tackles the big questions of how to develop the basic craft of the thinking required in high-tech companies. Drawing from basic economic principles and practical experience in the semiconductor business, it breaks new ground in our understanding of the complexities of high-tech execution.

'A terrifying story of profit before patients, and a chilling glimpse of what can happen when private companies are allowed to take charge of healthcare.' Gavin Francis Six decades ago, researchers achieved the impossible: developing a treatment that transformed kidney failure from a death sentence to a manageable condition. Yet, in the hands of a predatory medical industry, this triumph led to skyrocketing costs and worsening care. A gripping account of privatised healthcare gone wrong, How to Make a Killing recounts how the optimism of the 1950s and 1960s - when transplants and dialysis machines offered hope - gave way to anguished debates about the ethics of rationing and profiting from life-saving care, and how Big Dialysis proliferated at the expense of its patients. A triumph of investigative research, Tom Mueller's book features an unforgettable cast of characters: CEOs who dress as musketeers to exhort more aggressive profit-seeking, nephrologist insiders who reveal the substandard care this causes, and heroic patients who risk their lives to reveal the truth.

Translational Biotechnology: A Journey from Laboratory to Clinics presents an integrative and multidisciplinary approach to biotechnology to help readers bridge the gaps between fundamental and functional research. The book provides state-of-the-art and integrative views of translational biotechnology by covering topics from basic concepts to novel methodologies. Topics discussed include biotechnology-based therapeutics, pathway and target discovery, biological therapeutic modalities, translational bioinformatics, and system and synthetic biology. Additional sections cover drug discovery, precision medicine and the socioeconomic impact of translational biotechnology. This book is valuable for bioinformaticians, biotechnologists, and members of the biomedical field who are interested in learning more about this promising field.

The book examines the evolution of one of the most important technologies that has emerged in the last fifty years: biotechnology - the use of living organisms, or parts thereof to create useful products and services. The most important application of biotechnology has been in medicine, in the development of new drugs. The central purpose of the book is to explain how firms based in the US took the lead in commercialising the technology, and why it has been so difficult for firms in other countries to match what the leading American companies have achieved. The book looks at the institutions and policies which have underpinned US success in biotechnology. This is the US innovation "ecosystem," and it is made up of several interlocking elements which constitute a powerful competitive advantage for US biotechnology firms. These include, a higher education system which has close links with industry, massive support from the Federal government for biomedical research, and a financial system which is well equipped to support young entrepreneurial firms in a science-based industry. In the light of US experience the book examines in detail the performance of UK biotechnology firms over the past forty years, starting with the creation of the UK's first dedicated biotech firm, Celltech, in 1980. The book shows how the UK made a promising start in the 1980s and 1990s but failed to build on it. Several leading firms failed, and after an initial burst of enthusiasm investors lost confidence in the British biotech sector. It is only the last few years that the sector has staged a revival, attracting fresh investment from the US as well from the UK. The story told in this book, based on extensive interviews with industry participants, investors, and policy makers in the UK, Continental Europe, and the US, sheds new light on one of the central issues facing governments in the advanced industrial countries - how to create and sustain new science-based industries.

"Micropolitics and Canadian Business" explores the internal structure of industry politics in contemporary Canada. This "micropolitics" approach offers a revealing set of conceptual tools and models that illuminate the politics of everyday business at the industry, firm, and policy issue levels. It builds wider contexts in which the concrete particulars of business-government relations can be explored and understood in a systematic fashion.

The approach developed is a comparative one. The book examines three industries--paper, steel, and airlines--carefully chosen to represent a revealing cross-section of a vast economic field covering the primary (resource), secondary (manufacturing), and tertiary (service) sectors of the economy. In addition, one industry (pulp and paper) is primarily export-oriented, another (steel) focuses mainly on domestic sales, and the third (air transport) is strongly grounded in both.

The book applies to each a common set of questions and applies a similar set of methods. Separate chapters on each industry begin with a brief review of current industry concerns, followed by a historical and structural survey of that industry. Each chapter continues with studies of two leading firms, highlighting their internal politics and their strategic orientations. Since firms are the building blocks of industry, they tell us much about the larger structures of political power. Finally, each chapter examines two significant public policy controversies whose scope extends beyond core business boundaries.

"Micropolitics and Canadian Business" specifically analyzes three industries; however, the approach used may be applied to a much wider universe of companies and sectors. Throughout, this book furthers our understanding of the complex contexts of business politics. As such, it will be of interest to both students and practitioners of business and government relations.

Why is it that in the '90s, business in California's Silicon Valley flourished, while along Route 128 in Massachusetts it declined? The answer, Annalee Saxenian suggests, has to do with the fact that despite similar histories and technologies, Silicon Valley developed a decentralized but cooperative industrial system while Route 128 came to be dominated by independent, self-sufficient corporations. The result of more than one hundred interviews, this compelling analysis highlights the importance of local sources of competitive advantage in a volatile world economy.

Consumer electronics and computers redefined life and work in the twentieth century. In Inventing the Electronic Century, Pulitzer Prize-winning business historian Alfred D. Chandler, Jr. traces their origins and worldwide development. From electronics prime mover RCA in the 1920s to Sony and Matsushita's dramatic rise in the 1970s; from IBM's dominance in computer technology in the 1950s to Microsoft's stunning example of the creation of competitive advantage, this masterful analysis is essential reading for every manager and student of technology. "Thought provoking. Chandler develops the history of the consumer electronics and computer industries with the questioning attitude of a teacher: always searching for the lessons behind the story." --Andrew S. Grove, Chairman of the Board, Intel "Offers a rich cast of characters and companies, compelling stories, and deep understanding of economic forces." --Hal Varian, School of Information Management and Systems, University of California, Berkeley

Scientists in the biotechnology sector have developed a vast array of products and procedures, including drugs, diagnostics, agricultural products and veterinary procedures. This is made possible through various intra- and inter-organizational collaborations between the academic and private sectors, and through the establishment of networks for learning. In Networks for Learning and Knowledge Creation in Biotechnology, Amalya Lumerman Oliver shows how, in many respects, the organizational structure of the industry parallels one of its most important innovations - recombinant DNA (rDNA). She shows how the concept of recombination can be used to explain a number of organizational elements, including new biotechnology firms, the form of university-based spin-offs, scientific entrepreneurship, and trust and contracts in learning collaborations and networks. The result is a stimulating account of how multiple theoretical perspectives can be used to understand the structure of the biotechnology industry.

This book focuses on the challenges of competition in television broadcasting markets. How is the evolution from a two-sided market to platform economics reshaping competition in television broadcasting? How are new market dynamics changing competition for content creation and acquisition and the revenue streams? Will content remain king? Or will new competitive dynamics undermine the sustainable creation of high quality content, especially in small media markets?

Contemporary Medical Biotechnology Research for Human Health discusses a range of currently available solutions required to defeat the ever-increasing human health challenges. The junction between biotechnology and biomedical/health sciences has led to several improvements in patients' treatment, diagnosis and well-being. The book discusses vital topics ranging from biofilms and UTI, mycobacterial infections, diabetes, aplastic anemia, oral cancer, and possible applications of nanoparticles. In addition, it discusses computer-aided drug design using natural products and new technologies to develop antibiotics. This is a valuable resource for biotechnology and biomedical researchers, bioinformaticians and members of health sciences interested in understanding recent technological developments.

This book provides the basic models and methods for the profitable use and marketing of advanced technology. It provides a guide to developing and administering marketing plans, conducting market research, searching for and managing partners, tapping capital for innovation, scoping adequate pricing methods, managing intellectual property rights, and selling and distributing products and services. It also shows how to develop formatted business plans for investors. This title is uniquely focused on the critical technology/market interface, and provides an executive introduction to marketing these products and services.

During the 1970s and 1980s, American manufacturing enterprises saw their technological dominance challenged by increasingly tough competition from abroad. This book investigates business responses to those challenges. On average, F. M. Scherer shows, 308 U.S. companies reacted to rising imports of high-technology products by cutting back research and development expenditures as a percentage of sales. The cutbacks were particularly large in industries protected by voluntary trade restraint agreements and other trade barriers. Using statistical data and eleven in-depth case studies, Scherer finds that company responses to new high-technology competition from abroad were highly diverse. Aggressive reactions predominated in firms producing color film, wet shavers, medical imaging apparatus, fiber optics, and earth-moving equipment. But the efforts of U.S. manufacturers in other lines such as color television, VCRs, and facsimile machines were too meager to repel technologically innovative overseas challengers. Exploring why reactions differed so much from case to case, Scherer finds systematic explanations in such variables as the multinationality of enterprises, domestic market structure, links to academic science bases, and the educational background of top managers. He concludes by offering proposals to improve the competitiveness of American high-technology companies.

Transcultural Artificial Intelligence and Robotics in Health and Social Care provides healthcare professionals with a deeper understanding of the incredible opportunities brought by the emerging field of AI robotics. In addition, it provides robotic researchers with the point-of-view of healthcare professionals to understand what the healthcare sector - as well as the market - really needs from robotics technology. By doing so, the book fills an important gap between both fields in order to leverage new developments and collaborative work in favor of global patients. The book is aimed at the non-technical reader, especially health and social care professionals, and explains in a simple way the technological principles applied in the development of socially assistive humanoid AI robots (SAHR), the values which guide such developments, the ethics related to them, and research approaches in the field, with a focus on achieving a culturally competent SAHR.

Roadmap to Successful Digital Health Ecosystems: A Global Perspective presents evidence-based solutions found on adopting open platforms, standard information models, technology neutral data repositories, and computable clinical data and knowledge (ontologies, terminologies, content models, process models, and guidelines), resulting in improved patient, organizational, and global health outcomes. The book helps engaging countries and stakeholders take action and commit to a digital health strategy, create a global environment and processes that will facilitate and induce collaboration, develop processes for monitoring and evaluating national digital health strategies, and enable learnings to be shared in support of WHO's global strategy for digital health. The book explains different perspectives and local environments for digital health implementation, including data/information and technology governance, secondary data use, need for effective data interpretation, costly adverse events, models of care, HR management, workforce planning, system connectivity, data sharing and linking, small and big data, change management, and future vision. All proposed solutions are based on real-world scientific, social, and political evidence.

Bioinformatics for Everyone provides a brief overview on currently used technologies in the field of bioinformatics-interpreted as the application of information science to biology- including various online and offline bioinformatics tools and softwares. The book presents valuable knowledge in a simplified way to help students and researchers easily apply bioinformatics tools and approaches to their research and lab routines. Several protocols and case studies that can be reproduced by readers to suit their needs are also included.

Micro and Nano Systems for Biophysical Studies of Cells and Small Organisms provides a comprehensive introduction to the state-of-the-art micro and nano systems that have recently been developed and applied to biophysical studies of cells and small organisms. These micro and nano systems span from microelectromechanical systems (MEMS) and microfluidic devices to robotic micro-nanomanipulation systems. These biophysical studies range from cell mechanics to the neural science of worms and Drosophila. This book will help readers understand the fundamentals surrounding the development of these tools and teach them the most recent advances in cellular and organismal biophysics enabled by these technologies.

This book integrates the experimental procedures and theoretical principles for undergraduate, postgraduate, academicians and researchers in the area of agriculture and life sciences. The experiments have been updated and extended to reflect developments in the respective fields. In-text worked examples are again used to enhance student’s understanding of each topic. The book is designed to provide students with the experience of how scientists use their knowledge to understand real-world science related issues that confront them in their professional lives. Experimental procedures and troubleshooting of data are emphasised throughout the book. The book integrates theory and practices to ensure students understand why and how each technique is used.

The Electronic Health Record: Ethical Considerations analyses the ethical issues that surround the construction, maintenance, storage, use, linkage, manipulation and communication of electronic health records. Its purpose is to provide ethical guidance to formulate and implement policies at the local, national and global level, and to provide the basis for global certification in health information ethics. Electronic health records (EHRs) are increasingly replacing the use of paper-based records in the delivery of health care. They are integral to providing eHealth, telehealth, mHealth and pHealth - all of which are increasingly replacing direct and personal physician-patient interaction - as well as in the developing field of artificial intelligence and expert systems in health care. The book supplements considerations that are raised by national and international regulations dealing with electronic records in general, for instance the General Data Protection Regulation of the European Union. This book is a valuable resource for physicians, health care administrators and workers, IT service providers and several members of biomedical field who are interested in learning more about how to ethically manage health data.

From acclaimed Financial Times columnist and CNN analyst Rana Foroohar, comes this penetrating indictment of how today's biggest tech companies are hijacking our data, our livelihoods, and our minds.

Today Google and Facebook receive 90% of the world's news ad-spending. Amazon takes half of all e-commerce in the US. Google and Apple operating systems run on all but 1% of cell phones globally. And 80% of corporate wealth is now held by 10% of companies - not the GEs and Toyotas of this world, but the digital titans. How did we get here? How did the tech industry get to dominate our world so completely? How did once-idealistic and innovative companies come to manipulate elections, violate our privacy, and pose a threat to the fabric of our democracy? In Don't Be Evil, Financial Times global business columnist Rana Foroohar documents how Big Tech lost its soul - and became the new Wall Street.

Through her skilled reporting and unparalleled access - won through nearly 30 years covering business and technology - she shows the true extent to which the 'Faang's (Facebook, Apple, Amazon, Netflix and Google) crush or absorb any potential competitors, hijack our personal data and mental space and offshore their exorbitant profits. What's more, she reveals how these threats to our democracies, our livelihoods and our minds are all intertwined. Yet Foroohar also lays out a plan for how we can resist, creating a framework that fosters innovation while also protecting us from the dark side of digital technology.

Single-Cell Omics: Volume 1: Technological Advances and Applications provides the latest technological developments and applications of single-cell technologies in the field of biomedicine. In the current era of precision medicine, the single-cell omics technology is highly promising due to its potential in diagnosis, prognosis and therapeutics. Sections in the book cover single-cell omics research and applications, diverse technologies applied in the topic, such as pangenomics, metabolomics, and multi-omics of single cells, data analysis, and several applications of single-cell omics within the biomedical field, for example in cancer, metabolic and neuro diseases, immunology, pharmacogenomics, personalized medicine and reproductive health. This book is a valuable source for bioinformaticians, molecular diagnostic researchers, clinicians and members of the biomedical field who are interested in understanding more about single-cell omics and its potential for research and diagnosis.

Biotechnology and law are inextricable. Patent, regulatory, and contract law profoundly shape the biotech industry, and each of these practice areas is deeply intertwined with the science it governs. Yet many in this industry lack even a basic grasp of these laws, jeopardizing their business success as a result. This book is an essential introduction to biotechnology law for scientists, startup founders, regulatory specialists, patent liaisons, investors, academics, students, and other nonattorneys with biotech backgrounds. It covers core topics such as patentability, patent prosecution and infringement, patent opinions, the development and FDA approval of small-molecule and biologic drugs, regulatory exclusivity, generic drugs and ANDA litigation, biosimilars and the patent dance, patent licenses, and collaboration agreements. Written with scientists in mind, Biotechnology Law is a clear, concise, and entirely practical primer on the topic, replete with straightforward, real-world examples to illustrate each key concept. Understanding the legal machinery through which science becomes business is not a luxury-it is a crucial part of a scientist's training. Alan J. Morrison's expert treatment embraces this new reality.

In Chapter One, Antonio Colmenar-Santos, Enrique Rosales-Asensio, David Borge-Diez, and Manuel Castro-Gil present an overview of current research on equitable alternatives for recently constructed concentrated solar power plants in Spain. Next, Chapter Two by Dian Andriani, Arini Wresta, Arifin Santosa, and Kusnadi discusses the idea that various raw materials can be used for biogas production. Additionally, the authors discuss modern biogas production technologies. In Chapter Three, Caroline Borges Agustini and Mariliz Gutterres provide a review on the significance of biogas production in conjunction with its characteristics and handling problems. Following this, the authors go on to review current microorganism identification techniques as well as crop optimisation techniques. In Chapter Five, Sina Gilassi, Seyed Mohammad Taghavi, Serge Kaliaguine, and Denis Rodrigue suggest commercial polymer hollow fibres could be used to improve separation efficiency and CH4 purity in biogas production. Vladimir I. Shcherbakov, Nadezhda V. Kuznetsova, and Tatiana V. Shchyukina present research with the goal of determining favourable conditions for methane forming bacteria vital functions, fermentation processes intensification methods, and developing advance capacity reactors in Chapter Six. Afterwards, Chapter Seven by Spyridon Achina and Vasileios Achinas deliberates on the physicochemical properties of biogas and the need for further research on the subject. In Chapter Eight, Kevin N. Nwaigwe, Uchenna C. Egbufor, Sambas N. Asoegwu, and Christopher C. Enweremadu propose water hyacinth as a substrate for biogas production. Chapter Nine by Preseela Satpathy, PhD examines recent trends in biogas technology advancements. Next, Chapter Ten by Caroline Borges Agustini and Mariliz Gutterres explores the anaerobic process characteristics of anaerobic digestion, as well as its efficiency. In Chapter Eleven, Mohamed Habib Sellami exhibits a modelling approach designed to hypothesise the performance, impact, and profitability of systems cogenerating energy from released biogas. In conclusion, Chapter Twelve by K. N. Nwaigwe, E. E. Anyanwu and C. C. Enweremadu presents a synopsis on bioreactor technology development trends.

The biohealthcare executive in upper-middle management confronts leadership challenges unique to their industry: they manage highly specialized knowledge workers and innovators, compete at the speed of technology, work in a highly regulated environment where "free speech" often does not apply due to patient safety and privacy concerns, and increasingly are leading virtual teams who may be located in different parts of the world. Practical leadership for biopharmaceutical executives is a guide that strips away the theory and meets head-on the practical leadership challenges these executives face on a daily basis, and provides these "innovator leaders" with the tools to lead effectively in the face of technological complexity.

With the advent of electronic medical records years ago and the increasing capabilities of computers, our healthcare systems are sitting on growing mountains of data. Not only does the data grow from patient volume but the type of data we store is also growing exponentially. Practical Predictive Analytics and Decisioning Systems for Medicine provides research tools to analyze these large amounts of data and addresses some of the most pressing issues and challenges where data integrity is compromised: patient safety, patient communication, and patient information. Through the use of predictive analytic models and applications, this book is an invaluable resource to predict more accurate outcomes to help improve quality care in the healthcare and medical industries in the most cost-efficient manner. Practical Predictive Analytics and Decisioning Systems for Medicine provides the basics of predictive analytics for those new to the area and focuses on general philosophy and activities in the healthcare and medical system. It explains why predictive models are important, and how they can be applied to the predictive analysis process in order to solve real industry problems. Researchers need this valuable resource to improve data analysis skills and make more accurate and cost-effective decisions.